ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

AI Assistance Boosts Consistency, Accuracy During Analysis of Skin Cancer Tissue

A recent study led by researchers at Karolinska Institute, in partnership with Yale University, has shown that artificial intelligence can significantly enhance the work of pathologists when examining skin cancer tissue samples. The use of AI made the assessments more reliable and helped provide a clearer picture of patient outcomes. 

One of the key factors in analyzing skin cancer, particularly malignant melanoma, is the presence of tumor-infiltrating lymphocytes (TILs). These are immune system cells located around or within tumors and play a crucial role in how the body responds to cancer. A higher count of TILs generally signals a stronger immune reaction and can be a good sign for the patient. For this reason, estimating the number of TILs is a standard part of diagnosing and evaluating skin cancer. 

In the recent study, researchers explored how the use of AI influenced the accuracy and reliability of TIL assessments. The experiment involved 98 participants, including professional pathologists and others with experience reviewing pathological images, split into two groups. 

The first group consisted entirely of seasoned pathologists who evaluated digital slides of tissue samples using traditional methods, following established guidelines. The second group, consisting of pathologists and other researchers, also reviewed the same slides, but with the help of an AI tool trained to count TILs. 

Each participant reviewed 60 samples from past melanoma cases, meaning the outcomes and treatments were already known. This setup allowed the researchers to compare the assessments to actual patient histories. 

The findings revealed that those who used the AI tool produced more reliable and consistent evaluations. Regardless of who did the review, the results were remarkably similar within the AI-assisted group. Normally, TIL assessments can vary depending on who is doing the evaluation, which may affect patient care. 

However, with AI support, the assessments showed high agreement across reviewers. This suggests a step forward in reducing human error and increasing diagnostic accuracy. The AI-assisted reviews also aligned more closely with the actual outcomes of the patients, highlighting the tool’s potential to help guide treatment decisions in the future. 

According to Balazs Acs, the study’s senior author and a clinical pathologist at Karolinska Institutet, having a reliable tool to measure TILs could influence how aggressively skin cancer is treated. While more research is needed before the technology becomes part of standard medical practice, the early findings suggest it could help doctors better understand disease severity and plan treatment more effectively. 

AI is already being extensively used in other fields, such as marketing and branding, by companies like Thumzup Media Corp. (NASDAQ: TZUP). It is also finding increasing use within the medical field. The tests being made to deploy it during skin cancer diagnosis and monitoring is therefore a natural step forward that could result in better care for patients. 

About AINewsWire

AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer

AINewsWire
Los Angeles, CA
www.AINewsWire.com
310.299.1717 Office
Editor@AINewsWire.com

AINewsWire is powered by IBN

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.